US4748175A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pyrimido[5,4-B][1,4]oxazine derivatives and pharmaceutical compositions containing them
Assignee: Chinoin Private Co Ltd
•
Filing: 1986-12-30
•
Granted: 1988-05-31
•
Expires: 2006-12-30
Abstract
Abstract The invention relates to novel pyrimido [5,4-b][1,4]oxazine derivatives of the formula (I), and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## wherein R 1 stands for a C 1-4 alkyl group; R 2 stands for hydrogen or halogen or an azido group or an --NR 5 R 6 group, wherein R 5 represents hydrogen or a benzyl group, or a C 1-4 alkyl group unsubstituted or substituted by a hydroxyl group, R 6 stands for hydrogen, an amino group, a C 3-6 cycloalkyl group, a straight or branched-chain C 1-4 alkyl group optionally substituted by a hydroxyl, mercapto, aminocarbonyl, furyl, 2-benzo[1,4]dioxanyl, di(C 1-4 alkyl)amino group or by a phenyl or phenoxy group optionally mono- or polysubstituted by halogen or C 1-4 alkoxy group (s) or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 1-4 alkyl or benzyl group; further NR 5 R 6 may also represents a 6-membered, saturated, nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 2-4 alkoxycarbonyl or C 1-4 hydroxyalkyl group; R 3 and R 4 are the same or different and stand for hydrogen or a C 1-4 alkyl group; R 9 stands for hydrogen or a C 1-4 alkyl group unsubstituted or monosubstituted by an oxo, cyano, aminocarbonyl, C 2-5 alkoxycarbonyl, pyridiyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by OH group(s), with the proviso that R 2 is different from chlorine, 4-morpholinyl and piperidyl group when R 9 stands for hydrogen; or R 2 is different from chlorine and 4-morpholinyl group when R 9 stands for a methyl or benzyl group. The compounds of the formula (I) are capable to increase the myocardial contractile force (the performance of the failing heart) and the coronary blood flow, thus they can therapeutically be used for the treatment of the chronic heart failure and coronary disturbances.
Inventors
- 👤 Endre Kasztreiner
- 👤 Gyorgy Rabloczky
- 👤 Nandor Makk
- 👤 Gyorgy Cseh
- 👤 Maria Kuhar nee Kurthy
- 👤 Eszter Diesler
- 👤 Laszlo Jaszlits
- 👤 Laszlo Sebestyen
- 👤 Janos Wellmann
- 👤 Aniko Tegdes
- 👤 Judit Sarossy nee Kincsesy
- 👤 Peter Matyus
- 👤 Andras Varro
- 👤 Laszlo Szam
- 👤 Sarolta Vegvari nee Gyurki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 17:30
CPC Classifications
C; C07; C07D; C07D498/00; C07D498/02; C07D498/04; A; A61; A61P; A61P9/00; A61P9/04; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
223 words
A compound of the Formula (I), ##STR4## wherein R 1 stands for a C 1-4 alkyl group; R 2 stands for halogen or an --NR 5 R 6 group, wherein R 5 represents hydrogen or a benzyl group R 6 stands for hydrogen, a straight or branched-chain C 1-4 alkyl group optionally substituted by a hydroxyl, di(C 1-4 alkyl)amino group or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a methyl or benzyl group; further NR 5 R 6 may also represent a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 2-4 alkoxycarbonyl or C 1-4 hydroxyalkyl group; R 3 and R 4 are the same or different and stand for hydrogen or a methyl group; R 9 stands for hydrogen or a C 1-3 alkyl group unsubstituted or monosubstituted by an oxo, cyano, C 2-5 alkoxycarbonyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by a OH group, with the proviso that R 2 is different from a chlorine, 4-morpholinyl or piperidyl group when R 9 stands for hydrogen; or R 2 is different from a chlorine or 4-morpholinyl group when R 9 stands for a methyl or benzyl group, or a tautomer, tautomeric mixture or pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
223 words
A compound of the Formula (I), ##STR4## wherein R 1 stands for a C 1-4 alkyl group; R 2 stands for halogen or an --NR 5 R 6 group, wherein R 5 represents hydrogen or a benzyl group R 6 stands for hydrogen, a straight or branched-chain C 1-4 alkyl group optionally substituted by a hydroxyl, di(C 1-4 alkyl)amino group or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a methyl or benzyl group; further NR 5 R 6 may also represent a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 2-4 alkoxycarbonyl or C 1-4 hydroxyalkyl group; R 3 and R 4 are the same or different and stand for hydrogen or a methyl group; R 9 stands for hydrogen or a C 1-3 alkyl group unsubstituted or monosubstituted by an oxo, cyano, C 2-5 alkoxycarbonyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by a OH group, with the proviso that R 2 is different from a chlorine, 4-morpholinyl or piperidyl group when R 9 stands for hydrogen; or R 2 is different from a chlorine or 4-morpholinyl group when R 9 stands for a methyl or benzyl group, or a tautomer, tautomeric mixture or pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
27 words
The compound of the Formula (I) defined in claim 1 wherein R 1 is methyl, or a tautomer, tautomeric mixture, or pharmaceutically acceptable acid addition salt thereof.
Claim 4
Dependent Claim
37 words
The compound of the Formula (I) defined in claim 1 wherein R 2 is --NR 5 R 6 and --NR 5 R 6 is 4-morpholinyl, or a tautomeric, tautomeric mixture or pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
49 words
The compound of the Formula (I) defined in claim 1 wherein R 2 is --NR 5 R 6 , R 5 is hydrogen and R 6 is selected from the group consisting of 2-(4-morpholinyl)-ethyl, (4-benzyl-2-morpholinyl)-methyl and 3-(4-morpholinyl)-propyl, or a tautomer, tautomeric mixture, or pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim
34 words
A compound selected from the group consisting of 2-methyl-4-[2-(4-morpholinyl)-ethyl]-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-[N-benzyl-N-(2-hydroxyethyl)]-amino-2-methyl-6-7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 2-methyl-4-[3-(4-morpholinyl)-propyl]-amino-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-chloro-8-(2,3-dihydroxypropyl)-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 8-(2,3-dihydroxypropyl)-2-methyl-4-(4-morpholinyl)-6,7-dihydro-8H-pyrimido[5,4-b][1,4]-oxazin-7-one, 4-[(4-benzyl-2-morpholinyl)-methyl]-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 8-ethoxycarbonylmethyl-4-(2-hydroxyethyl)-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-(2-hydroxyethyl)-amino-2-methyl-8-(2-oxopropyl)-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-(2-hydroxyethyl)-amino-2-methyl-8-(4-morpholinyl-carbonyl)-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]-oxazin-7-one, 8-(n-butoxycarbonyl)-methyl-4-(2-hydroxyethyl)-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]-oxazin-7-one, 8-benzyl-4-(2-hydroxyethyl)-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, and 4-amino-8-ethoxycarbonylmethyl-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one or a tautomer, tautomeric mixture or a pharmaceutically acceptable acid addition salt thereof.
Claim 7
Dependent Claim
34 words
A compound selected from the group consisting of 2-methyl-4-[2-(4-morpholinyl)-ethyl]-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-[N-benzyl-N-(2-hydroxyethyl)]-amino-2-methyl-6-7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 2-methyl-4-[3-(4-morpholinyl)-propyl]-amino-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-chloro-8-(2,3-dihydroxypropyl)-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 8-(2,3-dihydroxypropyl)-2-methyl-4-(4-morpholinyl)-6,7-dihydro-8H-pyrimido[5,4-b][1,4]-oxazin-7-one, 4-[(4-benzyl-2-morpholinyl)-methyl]-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 8-ethoxycarbonylmethyl-4-(2-hydroxyethyl)-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-(2-hydroxyethyl)-amino-2-methyl-8-(2-oxopropyl)-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, 4-(2-hydroxyethyl)-amino-2-methyl-8-(4-morpholinyl-carbonyl)-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]-oxazin-7-one, 8-(n-butoxycarbonyl)-methyl-4-(2-hydroxyethyl)-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]-oxazin-7-one, 8-benzyl-4-(2-hydroxyethyl)-amino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one, and 4-amino-8-ethoxycarbonylmethyl-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one or a tautomer, tautomeric mixture or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Dependent Claim
12 words
2-methyl-4-[2-(4-morpholinyl)-ethyl]-amino-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one or the dihydrochloride or fumarate thereof as defined in claim 5.
Claim 9
Dependent Claim
39 words
A pharmaceutical composition which comprises as active ingredient a compound of the formula (I), as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry.
Claim 10
Independent Claim
304 words
A method of treating chronic heart failure or coronary disturbances in a mammalian subject which comprises the step of administering to said mammalian subject a therapeutically effective amount of a compound of the Formula (I) ##STR5## wherein R 1 stands for a C 1-4 alkyl group; R 2 stands for hydrogen or halogen or an azido group or an --NR 5 R 6 group, wherein R 5 represents hydrogen or a benzyl group or a C 1-4 alkyl group unsubstituted or substituted by a hydroxyl group, R 6 stands for hydrogen, an amino group, a C 3-6 cycloalkyl group, a straight or branched-chain C 1-4 alkyl group optionally substituted by a hydroxyl, mercapto, aminocarbonyl, furyl, 2-benzo[1,4]-dioxanyl, di(C 1-4 alkyl)amino group or by a phenyl or phenoxy group optionally mono- or polysubstituted by halogen or C 1-4 alkoxy group(s) or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 1-4 alkyl or benzyl group; further NR 5 R 6 may also represent a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 2-4 alkoxycarbonyl or C 1-4 hydroxyalkyl group; R 3 and R 4 are the same or different and stand for hydrogen or a C 1-4 alkyl group; R 9 stands for hydrogen or a C 1-4 alkyl group unsubstituted or monosubstituted by an oxo, cyano, aminocarbonyl, C 2-5 alkoxycarbonyl, pyridyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by OH group(s), with the proviso that R 2 is different from chlorine, 4-morpholinyl and piperidyl group when R 9 stands for hydrogen; or R 2 is different from chlorine and 4-morpholinyl group when R 9 stands for a methyl or benzyl group, or a tautomer, tautomeric mixture, or pharmaceutically acceptable acid addition salt thereof.
Claim 11
Independent Claim
304 words
A method of treating chronic heart failure or coronary disturbances in a mammalian subject which comprises the step of administering to said mammalian subject a therapeutically effective amount of a compound of the Formula (I) ##STR5## wherein R 1 stands for a C 1-4 alkyl group; R 2 stands for hydrogen or halogen or an azido group or an --NR 5 R 6 group, wherein R 5 represents hydrogen or a benzyl group or a C 1-4 alkyl group unsubstituted or substituted by a hydroxyl group, R 6 stands for hydrogen, an amino group, a C 3-6 cycloalkyl group, a straight or branched-chain C 1-4 alkyl group optionally substituted by a hydroxyl, mercapto, aminocarbonyl, furyl, 2-benzo[1,4]-dioxanyl, di(C 1-4 alkyl)amino group or by a phenyl or phenoxy group optionally mono- or polysubstituted by halogen or C 1-4 alkoxy group(s) or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 1-4 alkyl or benzyl group; further NR 5 R 6 may also represent a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C 2-4 alkoxycarbonyl or C 1-4 hydroxyalkyl group; R 3 and R 4 are the same or different and stand for hydrogen or a C 1-4 alkyl group; R 9 stands for hydrogen or a C 1-4 alkyl group unsubstituted or monosubstituted by an oxo, cyano, aminocarbonyl, C 2-5 alkoxycarbonyl, pyridyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by OH group(s), with the proviso that R 2 is different from chlorine, 4-morpholinyl and piperidyl group when R 9 stands for hydrogen; or R 2 is different from chlorine and 4-morpholinyl group when R 9 stands for a methyl or benzyl group, or a tautomer, tautomeric mixture, or pharmaceutically acceptable acid addition salt thereof.
Claim 12
Dependent Claim
30 words
The method of treatment defined in claim 8 wherein the compound of the Formula (I) or a tautomer, tautomeric mixture or pharmaceutically acceptable acid addition salt thereof is enterally administered.
Claim 13
Dependent Claim
30 words
The method of treatment defined in claim 8 wherein the compound of the Formula (I) or a tautomer, tautomeric mixture or pharmaceutically acceptable acid addition salt thereof is parenterally administered.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-05-31 | 1991-11-30 | 1992-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-05-31 | 1995-11-30 | 1996-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-05-31 | 1999-11-30 | 2000-05-31 | $7700.00 | Window Closed / Lapsed |